quantdetect

Received venture capital fund from MIRAIDOOR Tohoku.

OTS-Probes developed by Quantdetect were used for validation of rare variant quantification using automated DNA extraction and digital PCR in collaborative work with QIAGEN and Iwate Medical University.

Takeshi Iwaya, M.D., Ph.D. from the Department of Clinical Oncology, Iwate Medical University, presented an interim analysis of a prospective randomized trial using OTS-Assay (CHANGE study) at the 23rd Annual Meeting of the Japanese Society of Medical Oncology.

Ten OTS-Assay-related studies were presented at the 10th Liquid Biopsy meeting (Kyoto).

Nishizuka gave a talk in Session 2 at the 10th Liquid Biopsy 2026 meeting, sponsored by Quantdetect, Inc (Kyoto).

Nishizuka gave a talk on the OTS-Assay at the Evening Seminar of the 21st TR Workshop of the Japanese Association for Molecular Target Therapy of Cancer (Tokyo).